Aptar Pharma, a global leader in drug delivery and active material science solutions, has announced the acquisition of the clinical trial materials manufacturing arm of Mod3 Pharma (formerly Enteris Biopharma) from SWK Holdings. The move expands Aptar’s capabilities in formulation, fill and finish services for Phase 1 and 2 clinical trials, particularly for orally inhaled and nasal drug products (OINDPs).

This acquisition builds on a successful partnership between the two companies, helping meet a critical market gap in early-phase clinical trial supply. The facility in Boonton, New Jersey—now part of Aptar’s operations—is FDA-inspected and houses cGMP cleanrooms, suites for high-potency APIs and biologics, and advanced fill-finish technologies.

Aptar Pharma will now offer integrated services supporting early-stage drug development, device adoption, and the acceleration of innovative therapies across multiple delivery routes—including inhalation, dermal, ophthalmic, injectables, and secondary packaging—using its proprietary active material science platforms.

“This is a natural extension of our vision—‘from formulation to patient’,” said Gael Touya, President of Aptar Pharma. “By integrating clinical manufacturing, we’re enabling faster, more seamless development for our customers.”

Sai Shankar, President of M&A and Strategy at Aptar, added, “This acquisition allows us to deepen our innovation in drug delivery without overlapping with the strengths of our long-standing partners. It enhances our ability to deliver specialised, end-to-end support.”

Dr. Paul Shields, CEO of Mod3 Pharma, welcomed the move, stating, “Joining Aptar allows us to accelerate the impact of our work and more efficiently bring therapies to patients.”

With this acquisition, Aptar strengthens its position as a partner of choice for pharma innovators looking to streamline early development and commercialisation of complex drug products.